Literature DB >> 23060119

Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery?

Xiao Chloe Wan1, Ann Marie Egloff, Jonas Johnson.   

Abstract

OBJECTIVES/HYPOTHESIS: Postoperative chemoradiation (CRT) has been shown to be more effective than postoperative radiotherapy (RT) alone in high risk head and neck squamous cell carcinoma (HNSCC) patients. Multimodality therapy is associated with more treatment related-toxicity. In this study, we assessed cervical lymph node histological characteristics to detect prognostic and predictive value differences to help guide therapeutic decision making. STUDY
DESIGN: Retrospective analysis of Cancer Registry data.
METHODS: HNSCC surgical patients who had tumor resection and neck dissection at our institution from 1980 to 2008 were identified (n=1510). Multivariable Cox proportional hazards regression models were developed to identify significant predictors of three outcomes: overall survival (OS), disease-specific survival (DSS), and neck disease recurrence (NDR). Hazard ratios were estimated for the number of cervical nodal metastases and presence of extracapsular spread (ECS) by adjuvant treatment after controlling for significant covariates.
RESULTS: Increasing number of positive nodes was significantly associated with poorer outcomes in OS, DSS, and NDR models (p<0.0001, p<0.0001, p=0.0002, respectively). OS and DSS associated with adjuvant treatment (none, RT, or CRT) were modified by number of positive nodes, ECS status, and cancer site. The presence of ECS was associated with reduced OS and DSS (p=0.077, p=0.001 respectively), but not significantly associated with NDR (p=0.179). Nodal positive patients benefited from adjuvant therapy regardless of ECS status. CRT consistently conferred a survival advantage over RT across all nodal categories, although the difference was not statistically significant.
CONCLUSIONS: We observed a consistent survival advantage with CRT over RT for patients with positive cervical nodal metastasis, although the difference was not statistically significant.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23060119      PMCID: PMC3522766          DOI: 10.1002/lary.23572

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  20 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Authors:  Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

4.  Extent of extracapsular spread: a critical prognosticator in oral tongue cancer.

Authors:  Jayson S Greenberg; Robert Fowler; Jose Gomez; Vivian Mo; Dianna Roberts; Adel K El Naggar; Jeffrey N Myers
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

5.  Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer.

Authors:  K K Ang; A Trotti; B W Brown; A S Garden; R L Foote; W H Morrison; F B Geara; D W Klotch; H Goepfert; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

Review 6.  Neck disease and distant metastases.

Authors:  Eric M Genden; Alfio Ferlito; Patrick J Bradley; Alessandra Rinaldo; Crispian Scully
Journal:  Oral Oncol       Date:  2003-04       Impact factor: 5.337

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

Review 8.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

Review 9.  Head and neck cancer.

Authors:  Athanassios Argiris; Michalis V Karamouzis; David Raben; Robert L Ferris
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

Review 10.  Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck.

Authors:  C Ko; D Citrin
Journal:  Oral Dis       Date:  2008-11-11       Impact factor: 3.511

View more
  6 in total

1.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

2.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Authors:  Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

3.  How is neck dissection performed in Oral and Maxillofacial Surgery? Results of a representative nationwide survey among university and non-university hospitals in Germany.

Authors:  Andreas Pabst; Daniel G E Thiem; Elisabeth Goetze; Alexander K Bartella; Michael T Neuhaus; Jürgen Hoffmann; Alexander-N Zeller
Journal:  Clin Oral Investig       Date:  2021-03-29       Impact factor: 3.573

Review 4.  Adding Concomitant Chemotherapy to Postoperative Radiotherapy in Oral Cavity Carcinoma with Minor Risk Factors: Systematic Review of the Literature and Meta-Analysis.

Authors:  Alessia Di Rito; Francesco Fiorica; Roberta Carbonara; Francesca Di Pressa; Federica Bertolini; Francesco Mannavola; Frank Lohr; Angela Sardaro; Elisa D'Angelo
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

5.  Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity.

Authors:  M Hoffmann; L Saleh-Ebrahimi; F Zwicker; P Haering; A Schwahofer; J Debus; P E Huber; F Roeder
Journal:  Radiat Oncol       Date:  2015-12-04       Impact factor: 3.481

6.  ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.

Authors:  Maja Guberina; Ali Sak; Christoph Pöttgen; Ingeborg Tinhofer-Keilholz; Volker Budach; Panagiotis Balermpas; Jens Von der Grün; Claus Michael Rödel; Eleni Gkika; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Claus Belka; Steffi Pigorsch; Stephani E Combs; David Mönnich; Daniel Zips; Chiara De-Colle; Stefan Welz; Annett Linge; Fabian Lohaus; Gustavo Baretton; Thomas Gauler; Michael Baumann; Mechthild Krause; Martin Schuler; Agnes Bankfalvi; Benedikt Höing; Stephan Lang; Martin Stuschke
Journal:  Pharmacogenomics J       Date:  2020-06-16       Impact factor: 3.550

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.